Samsung Biologics declares PolyPeptide offer successful, subject to remaining conditions

Samsung Biologics declared its offer for PolyPeptide successful, subject to remaining conditions, with its subsidiary and concert parties holding 87.92%. A total of 29,014,418 shares were tendered by October 12, 2026, representing 87.59% of issued share capital. Completion is now expected in late 2026 or first-quarter 2027, rather than November 13, pending regulatory clearances and shareholder resolutions. The additional acceptance period runs from October 19 through October 30, 2026, ending at 4 p.m. Swiss time. Samsung Peptide intends to squeeze out remaining public shareholders and seek delisting from SIX following settlement. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPeptide Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2416952_en) on October 16, 2026, and is solely responsible for the information contained therein. (C)